HC Wainwright Brokers Boost Earnings Estimates for TRDA

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Analysts at HC Wainwright raised their Q4 2024 earnings estimates for shares of Entrada Therapeutics in a report issued on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.66) for the quarter, up from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.98 per share.

Separately, Oppenheimer boosted their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday.

Entrada Therapeutics Stock Up 3.1 %

TRDA opened at $19.23 on Friday. The firm has a market cap of $719.59 million, a PE ratio of 12.09 and a beta of -0.26. The business has a fifty day simple moving average of $16.36 and a 200-day simple moving average of $15.63. Entrada Therapeutics has a fifty-two week low of $10.75 and a fifty-two week high of $19.85.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.90. The firm had revenue of $94.69 million during the quarter, compared to analysts’ expectations of $55.00 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%.

Insider Buying and Selling

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78. Following the sale, the insider now directly owns 183,816 shares of the company’s stock, valued at $2,773,783.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 2,642 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the completion of the sale, the insider now directly owns 183,816 shares in the company, valued at approximately $2,773,783.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Nathan J. Dowden sold 1,904 shares of Entrada Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.07, for a total value of $28,693.28. Following the transaction, the chief operating officer now directly owns 125,996 shares in the company, valued at approximately $1,898,759.72. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,187 shares of company stock valued at $155,947. Company insiders own 7.59% of the company’s stock.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of TRDA. Allspring Global Investments Holdings LLC raised its holdings in shares of Entrada Therapeutics by 427.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after purchasing an additional 13,742 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Entrada Therapeutics during the 1st quarter valued at about $79,000. Bank of New York Mellon Corp grew its stake in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after buying an additional 14,838 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after buying an additional 7,452 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.